NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance

Oncotarget

Volumn 6, Issue 40, 2015, Pages 42569-42574

  Martner, Anna ^a   Rydström, Anna ^a   Riise, Rebecca E ^a   Aurelius, Johan ^a,b   Brune, Mats ^b   Foà, Robin ^c   Hellstrand, Kristoffer ^a   Thorén, Fredrik B ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myeloid leukemia; Immunotherapy; Natural killer cells; NKp30; NKp46

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; HISTAMINE; MEMBRANE RECEPTOR; NATURAL CYTOTOXICITY RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG; ALDESLEUKIN; ANTINEOPLASTIC AGENT; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; INTERLEUKIN 2; NCAM1 PROTEIN, HUMAN; NCR1 PROTEIN, HUMAN; NCR3 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL EXPANSION; CONSOLIDATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPHOCYTE FUNCTION; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; OVERALL SURVIVAL; PHASE 4 CLINICAL TRIAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE RISK; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CLINICAL TRIAL; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE SUBPOPULATION; MIDDLE AGED; MORTALITY; PROCEDURES; REMISSION; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD56; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HISTAMINE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE SUBSETS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, IGG; RECOMBINANT PROTEINS; REMISSION INDUCTION; YOUNG ADULT;

EID: 84952332380     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5559     Document Type: Article

References (24)

1. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23:1969-78.
2. Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31:1293-301.
3. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005; 106:1154-63.
4. Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M, Swedish Acute Leukemia Registry G. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012; 119:3890-9.
5. Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J Immunol. 1994; 153:4940-7.
6. Hellstrand K, Hermodsson S. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. International archives of allergy and applied immunology. 1990; 92:379-89.
7. Martner A, Thoren FB, Aurelius J, Hellstrand K. Immunotherapeutic strategies for relapse control in acute myeloid leukemia. Blood reviews. 2013; 27:209-16.
8. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006; 108:88-96.
9. Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer immunology, immunotherapy: CII. 2011; 60:1195-205.
10. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007; 109:323-30.
11. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002; 99:3661-7.
12. Tajima F, Kawatani T, Endo A, Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund. UK: 1996; 10:478-82.
13. Caligiuri MA. Human natural killer cells. Blood. 2008; 112:461-9.
14. Romagnani C, Juelke K, Falco M, Morandi B, D'Agostino A, Costa R, et al. CD56brightCD16-killer Ig-like receptor-NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol. 2007; 178:4947-55.
15. Babor F, Fischer JC, Uhrberg M. The role of KIR genes and ligands in leukemia surveillance. Frontiers in immunology. 2013; 4:27.
16. Lanier LL. NK cell recognition. Annual review of immunology. 2005; 23:225-74.
17. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annual review of immunology. 2013; 31:227-58.
18. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annual review of immunology. 2001; 19:197-223.
19. Martner A, Rydström A, Riise RE, Aurelius J, Anderson H, Brune M, Foa R, Hellstrand K. Thorén FB. Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. Oncoimmunolgy. 2015; DOI: 10.1080/2162402X.2015.1041701.
20. Gayoso I, Sanchez-Correa B, Campos C, Alonso C, Pera A, Casado JG, et al. Immunosenescence of human natural killer cells. Journal of innate immunity. 2011; 3:337-43.
21. Buyse M, Michiels S, Squifflet P, Lucchesi KJ, Hellstrand K, Brune ML, et al. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Haematologica. 2011; 96:1106-12.
22. Biassoni R, Bottino C, Cantoni C, Moretta A. Human natural killer receptors and their ligands. Current protocols in immunology/edited by John E Coligan et al. 2002. Chapter 14:Unit 14 0.
23. Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014; 99:836-47.
24. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115:453-74.